Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
99
resultados
Última actualización
26/07/2026 [06:59:00]
Resumen de: US20260207693A1
0000 An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.
Resumen de: US20260209750A1
Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.
Resumen de: US20260209766A1
0000 The present disclosure provides compositions and methods for treating and detecting coronavirus infection, and in particular, provides compositions and methods for treating and detecting SARS-CoV-2 infection. The present disclosure also relates to the production of compositions for treating and detecting coronavirus infection, and in particular, to the production of compositions for treating and detecting SARS-CoV-2 infection.
Resumen de: US20260207714A1
0000 Safe, effective, disease-modifying treatments—and especially, optimized treatments—for Alzheimer's and many other CNS, cardiovascular, metabolic and other disorders remain elusive. This is in part due to many CNS, cardiovascular, metabolic. and other disorders having underlying components on both sides of the blood-brain barrier—e.g., having CNS components as well as cardiovascular and/or metabolic and/or other non-CNS components. Respective examples in CNS, cardiovascular, metabolic and other domains include Alzheimer's disease, heart failure, diabetes and COVID-19. This is in and of itself a challenge, as most drugs (~98% of small molecules; a greater portion of larger molecules such as antibodies and peptides) do not cross the blood brain barrier appreciably, and even when they do, the chances of them having a partition coefficient that optimizes dosing in compartments on both sides of the blood brain barrier is vanishingly low. This invention addresses that challenge with a novel, bicameral, CNS+ (i.e., two-compartment, where one compartment is on the neuronal/glial side of the blood-brain barrier and one compartment is not) approach. This bicameral, CNS+ approach involves parallel 1) Intranasal, direct-to-brain delivery of drugs addressing the CNS component of a CNS, cardiovascular or metabolic disorder 2) Delivery (oral, injection or otherwise) of a cardiovascular &/or metabolic &/or other agent to the central compartment (i.e., blood and well-perfused org
Resumen de: US20260209180A1
0000 The present invention provides a compound of Formula I wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, and subscripts X and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.
0000
Resumen de: US20260209318A1
SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.
Resumen de: US20260209317A1
Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.
Resumen de: US20260207540A1
0000 Pharmaceutical compositions comprising at least one calcium chelating agent such as disodium ethylenediamine tetraacetate (Na2EDTA) as an active pharmaceutical ingredient, are described that are useful for treating an infection by single stranded RNA virus, such as SARS-COV-2, are described. Development of the compositions was assisted by using a novel drug discovery method which utilizes the characterization of a common molecular mechanism in a cohort of an unforeseen clinical co-morbidly patterns identified as outliers. Reverse engineering of the outlier cohort yielded unrecognized calcium requirements for infection by SARS-CoV-2 provided a common molecular mechanism in the outlier group that enabled formulation of the new pharmaceutical compositions.
Resumen de: US20260209778A1
0000 The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the transmembrane serine protein 2 (TMPRSS2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS2 gene and to methods of treating or preventing a TMPRSS2-associated disease, e.g., COVID-19, in a subject.
Resumen de: US20260209831A1
Methods and systems for detecting the presence of a target nucleic acid sequence in one or more samples of a plurality of samples are described. The methods may comprise the use of linear barcoded nucleic acid probes that, upon hybridization to a target nucleic acid sequence, may be ligated to circularize the probe molecule, amplified, and sequenced. The use of a probe-specific barcode integrated into the nucleic acid probe molecule, and sample-specific barcodes that may be incorporated into the nucleic acid probe molecule or added during the amplification step, enable large-scale multiplexed assay and sample processing.
Resumen de: US20260207541A1
0000 Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.
Resumen de: WO2025076406A1
The synthesis and characterization of a series of derivatives and analogs based on the 9-aminoacridine scaffold shared by antimalarial drugs quinacrine and pyronaridine are described. Also described is the structure-activity relationship of these compounds against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease of 2019 (COVID-19). Several compounds displayed potent in vitro activity, with 50% inhibitory concentrations below 1 micromolar.
Resumen de: WO2025059202A1
Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.
Resumen de: US20260201021A1
0000 Disclosed is a Fv-antibody having a specific binding ability to a cleavage site of a SARS-COV-2 spike protein by TMPRSS2. The Fv-antibody includes a peptide sequence of DPPPPAVAADV or CRDLLGVVRDF.
Resumen de: WO2026151918A1
Described herein are compositions and methods of using the same. The compositions can include a first nucleic acid encoding for an HPV E6 peptide or a variant or fragment thereof; a second nucleic acid encoding for an HPV E7 peptide or a variant or fragment thereof; and a third nucleic acid encoding a subdomain of the SARS-CoV-2 spike protein.
Resumen de: US20260201414A1
The present invention provides a method for producing coronavirus virus-like particles (VLPs) and a vaccine comprising the same. The method comprises: constructing a recombinant baculovirus carrying a coronavirus spike protein gene; transducing mosquito cells with the recombinant virus; and culturing the transduced cells in a serum-free medium to produce VLPs containing the coronavirus spike protein. Preferably, the mosquito cells are C6/36 cells, and the spike protein gene may be derived from SARS-COV, MERS-COV, or SARS-COV-2. Furthermore, the invention provides a vaccine containing the VLPs produced by the above method, which can be administered intranasally or by intramuscular injection.
Resumen de: WO2026151301A1
The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.
Resumen de: AU2026205187A1
COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 Abstract The present invention is directed to a compound herbal composition when used in treating COVID-19, comprising: Radix angelicae dahuricae; Herba moslae; Flos lonicerae japoni- cae; Semen sojae preparatum; Fructus momordicae; Rhizoma zingiberis recens; Radix platycodonis; Rhizoma phragmitis; Rhizoma imperatae; Fistular onion stalk; Radix et rhizome glycyrhizae; Fructus evodiae; Fructus alpiniae oxyphyllae; Fructus psoraleae; Fructus corni; Flower of Hyacinth Bean; Semen cuicis; and optionally together with up to about 1 wt% of one or more pharmaceutically acceptable excipients. COMBINED PLANT COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 un - u n b s t r a c t
Resumen de: EP4775268A2
The invention relates to an anti-coronavirus polypeptide as well as derivatives and application thereof, provides the anti-coronavirus polypeptide, and provides cholesterol-containing derivatives of the polypeptide on the basis of the anti-coronavirus polypeptide. Particularly, the original strain and the variant strain of the SARS-CoV-2 have an unexpected inhibition effect, can be used for preparing medicines or vaccines for preventing or treating the new coronavirus, and have great prevention or treatment potential.
Resumen de: KR20260109386A
본 발명은 RGS2 및 SPL의 발현 수준을 측정할 수 있는 제제를 포함하는 SARS-CoV-2 감염증 중증도 진단용 조성물에 관한 것이다. 본 발명의 SARS-CoV-2 감염증 환자의 중증도 진단용 조성물을 이용하는 경우, 고혈압을 앓고 있는 SARS-CoV-2 감염증 환자의 중증질환 진행 여부에 대해 진단하는 데 사용될 수 있다.
Resumen de: US20260196317A1
A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.
Resumen de: US20260193724A1
0000 A method for the detection of SARS-CoV-2 in a sample based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) of a target nucleic acid sequence. The RT-LAMP amplicons are detected by gold nanoparticles (AuNPs) functionalized with a probe specific for regions of the target sequence. Kits for the detection of SARS-CoV-2 in a sample are also provided wherein the kit comprises a reverse transcriptase, a polymerase, a primer set for reverse transcription loop-mediated isothermal amplification (RT-LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof, and a conjugated nanoparticle solution comprising gold, water, and a probe sequence that is at least 85% identical to SEQ ID No.: 1.
Resumen de: WO2026148343A1
Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.
Resumen de: WO2026148353A1
Provided are methods of suppressing an anti-oncolytic virus (anti-OV) antibody response to an oncolytic virus (OV) therapy. The methods comprise administering a B cell-depleting agent to a subject (e.g., a human subject) prior to and/or concurrently with administration of a therapeutic OV to the subject. Non-limiting examples of B cell-depleting agents include those that target CD19 or CD20. In some instances, a B cell-depleting agent comprises or consists of an antibody. In certain embodiments, the therapeutic OV administered to the subject is from the family Poxviridae, Herpesviridae, Adenoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviridae, Parvoviridae, or Coronaviridae. According to some embodiments, the B cell-depleting agent is administered (e.g., only administered) prior to and/or concurrently with an initial administration of the therapeutic OV to the subject. OV therapies of interest include, but are not limited to, OV cancer therapies.
Nº publicación: WO2026147882A1 09/07/2026
Solicitante:
TRAWS PHARMA INC [US]
TRAWS PHARMA, INC.
Resumen de: WO2026147882A1
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease using pharmaceutical composition disclosed herein. Provided a new combinatorial drag or a new pharmaceutical composition comprising compound of Formula (II-I-W-B), and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.
BOPI
Sede Electrónica
